Closing the last-mile gap in personalised medicine

Where personalised medicine becomes deliverable.

Personalised medicine is creating new possibilities for earlier diagnosis, targeted treatment, trial matching, risk-based prevention and more precise care. But scientific progress does not automatically become patient access. IPM Alliance focuses on the harder question: whether health systems are ready to identify eligible patients, activate the right pathways and deliver better care in time.

See more

The core problem

Science-rich. Pathway-poor.

Across oncology, rare diseases, cardiovascular and cardiometabolic disease, obesity and metabolic disease, immunology, neurology, diagnostics, biomarkers, AI-enabled healthcare and clinical trials, scientific progress is creating new opportunities for patients. Yet many systems still struggle to translate those opportunities into routine care. Diagnostic capacity may be uneven. Reimbursement may lag. Referral pathways may be fragmented. Data systems may not connect. Workforce capacity may be limited. Geography may decide who benefits first, late or not at all.

“Scientific progress creates eligibility. System readiness determines access.”

 

Scientific progress creates possibility

  • New diagnostics
  • Biomarkers
  • Targeted therapies
  • AI-enabled tools
  • Trial matching
  • Risk-based prevention

System gaps delay delivery

  • Uneven testing capacity
  • Reimbursement delays
  • Fragmented referral
  • Weak data infrastructure
  • Workforce shortages
  • Regional inequality

The IPM Answer

Implementation intelligence for personalised medicine

IPM Alliance is an international platform for personalised medicine implementation. It connects evidence, policy, access, stakeholder intelligence and practical delivery tools to help health systems understand where personalised medicine is ready, where it is blocked and what needs to change.

Intelligence

Signals, Alerts, Briefs and policy monitoring that explain what changed, why it matters and what should be watched next.

Disease Desks

Structured disease-specific intelligence on readiness, access, diagnostics, biomarkers, screening, care pathways and equity.

Stakeholder Insight

Analysis of how policymakers, clinicians, patients, payers, researchers, diagnostics leaders and innovators experience implementation barriers.

Implementation Labs

Multi-stakeholder sessions that turn access problems into prototypes, roadmaps, practical recommendations and follow-up actions.

The IPM Lens

Implementation intelligence for personalised medicine

IPM Alliance does not only report scientific, regulatory or policy developments. It interprets what they mean for implementation. For each major signal, decision or system change, IPM asks: who becomes eligible, what pathway should be activated, what barrier remains, which stakeholders need to act and what should be monitored next.

 

Signal to action

Trigger

New evidence, policy, approval, guideline or system decision

Eligibility

Which patients or systems are affected

Pathway

What should happen next

Bottleneck

What may block access

Stakeholder Action

Who needs to respond

Watchlist

What IPM will continue monitoring

The Patient Pathway

The patient does not experience innovation as a headline

For patients, personalised medicine is not experienced as a scientific article, regulatory decision or conference announcement. It is experienced as a pathway: being identified, tested, referred, treated, followed up and supported. IPM Alliance focuses on the points where that pathway succeeds, slows down or breaks.

Patient pathway line

1

Risk or symptoms

Missed eligibility

2

Identification

Delayed testing

3

Testing

Unclear referral

4

Specialist referral

Reimbursement gap

5

Treatment decision

Trial access gap

6

Access or reimbursement

Regional inequality

7

Follow-up and data

Weak follow-up data

What Makes IPM Different

A platform built around the implementation gap

Many platforms describe scientific progress. Others focus on policy debate. IPM Alliance connects the two by asking what scientific and policy changes mean for real-world delivery. The platform links evidence, access, stakeholder perspectives, pathway readiness, political attention and implementation follow-up into one structured intelligence model.

Evidence

Scientific studies, guidelines, regulatory decisions, HTA outputs, policy documents.

Interpretation

What changed, who is affected, what pathway is triggered, what barriers remain.

Stakeholder Intelligence

Public authorities, clinicians, patients, payers, researchers, diagnostics, industry, civil society.

Implementation Output

Signals, Alerts, Disease Desks, briefings, implementation labs, roadmaps, country assessments.

Trust and Independence

Neutral, evidence-informed and public-interest driven

IPM Alliance operates as a neutral, evidence-informed and multi-stakeholder platform. Its work is shaped by structured analysis, expert input and transparent methods. Partner or sponsor support may enable activities, but it does not determine editorial conclusions, policy positions, recommendations, speaker selection or outputs.

Evidence-informed

Built on official decisions, peer-reviewed evidence, policy documents, expert input and stakeholder intelligence.

Transparent methods

Structured taxonomy, clear source standards, editorial review and visible interpretation logic.

Editorially independent

Partner-supported activities do not control IPM conclusions, recommendations or policy positions.

Trust and Independence

Join the alliance working on the last mile

IPM Alliance brings together policymakers, clinicians, patients, researchers, health systems, diagnostics leaders, innovators, payers and civil society to build the conditions under which personalised medicine can reach the people who need it.

Policymakers

Patients

Clinicians

Health systems

Researchers

Diagnostics and pathology

Payers

Industry and innovators

Industry and innovators